SLC5A2 and diabetes mellitus: In the study by Marfella et al., which evaluated the expression of SGLT2 in human cells from diabetic and non-diabetic patients and in an AC16 myocardiocyte line from patients undergoing heart transplantation using immunohistochemistry, immunofluorescence and SGLT2 quantization with both real-time reverse transcription-polymerase chain reaction and Western blot analysis showed the presence of SGLT2 in patients with end-stage decompensation and that this expression is overexpressed in patients with diabetes mellitus.